Prospective Grant of an Exclusive Start-Up Option License: Potent and Selective Analogues of Monamine Transporters; Methods of Making; and Uses Thereof, 79594-79595 [2015-32141]
Download as PDF
<![CDATA[
79594
Federal Register / Vol. 80, No. 245 / Tuesday, December 22, 2015 / Notices
decision-making processes are
consistent with NEPA.
Need and Proposed Use of the
Information: Applicants must provide
information and assurance of
compliance with NEPA on the EID
checklist. This information is reviewed
in the Pre-Award stage.
Likely Respondents: HRSA applicants
applying for federal construction grants
and cooperative agreements.
Burden Statement: Burden in this
context means the time expended by
persons to generate, maintain, retain,
disclose, or provide the information
requested. This includes the time
needed to review instructions; to
develop, acquire, install, and utilize
technology and systems for the purpose
of collecting, validating and verifying
information, processing and
maintaining information, and disclosing
and providing information; to train
Number of
respondents
Form name
Number of
responses per
respondent
personnel and to be able to respond to
a collection of information; to search
data sources; to complete and review
the collection of information; and to
transmit or otherwise disclose the
information. The total annual burden
hours estimated for this Information
Collection Request are summarized in
the table below.
Total Estimated Annualized burden
hours:
Total
responses
Average
burden per
response
(in hours)
Total burden
hours
NEPA EID Checklist ............................................................
1,350
1
1,350
1.0
1,350
Total ..............................................................................
1,350
1
1,350
1.0
1,350
HRSA specifically requests comments
on (1) the necessity and utility of the
proposed information collection for the
proper performance of the agency’s
functions, (2) the accuracy of the
estimated burden, (3) ways to enhance
the quality, utility, and clarity of the
information to be collected, and (4) the
use of automated collection techniques
or other forms of information
technology to minimize the information
collection burden.
Jackie Painter,
Director, Division of the Executive Secretariat.
[FR Doc. 2015–32004 Filed 12–21–15; 8:45 am]
BILLING CODE 4165–15–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions;
Availability for Licensing
AGENCY:
National Institutes of Health,
HHS.
ACTION:
Notice
The inventions listed below
are owned by an agency of the U.S.
Government and are available for
licensing in the U.S. in accordance with
35 U.S.C. 209 and 37 CFR part 404 to
achieve expeditious commercialization
of results of federally-funded research
and development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Licensing information and copies of the
U.S. patent applications listed below
may be obtained by emailing the
indicated licensing contact at the
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:21 Dec 21, 2015
Jkt 238001
National Heart, Lung, and Blood, Office
of Technology Transfer and
Development Office of Technology
Transfer, 31 Center Drive Room 4A29,
MSC2479, Bethesda, MD 20892–2479;
telephone: 301–402–5579. A signed
Confidential Disclosure Agreement may
be required to receive copies of the
patent applications.
SUPPLEMENTARY INFORMATION:
Technology description follows.
Metallic Nanoparticles for
Photothermal Therapy
Description of Technology: The
invention relates to the preparation and
application of 20–150nm metallic
nanoparticulate vesicles for
photothermal anti-cancer therapy. The
vesicles comprise metallic nanoparticles
covalently bound to a hydrophilic and
hydrophobic polymer. The preparation
method generally entails dispersing a
polymer-bound metallic nanoparticle in
an organic solvent, adding an aqueous
solution with a dispersing aid,
sonicating the mixture, and finally
removing the organic solvent until the
vesicle forms. The final vesicle is stable
wherein the metallic nanoparticle is
covalently bound to the hydrophobic
and hydrophilic polymer. By way of a
non-limiting example, an exemplary
vesicles can be one made from gold
nanorods coated with polyethylene
glycol and polylactic-co-glycolic acid
(AuNR@PEG/PLGA) in an oil-in-water
emulsion.
Potential Commercial Applications:
• Cancer therapy
• Tumor therapy
Competitive Advantages:
• Prolonged circulation
• High tumor accumulation
• Rapid excretion
• Enhanced photoacoustic signal
PO 00000
Frm 00040
Fmt 4703
Sfmt 4703
• Enhanced photothermal effect/cancer
therapy efficacy.
Development Stage:
• In vitro data
Inventors: Xiaoyuan (Shawn) Chen
and Jibin Song (both of NIBIB).
Intellectual Property: HHS Reference
No. E–158–2015/0–US–01.
• U.S. Provisional Patent Application
62/226,289 filed December 11, 2015.
Licensing Contact: Michael
Shmilovich, Esq, CLP; 301–435–5019;
shmilovm@mail.nih.gov.
Collaborative Research Opportunity:
The National Institute of Biomedical
Imaging and Bioengineering seeks
statements of capability or interest from
parties interested in collaborative
research to further develop and evaluate
metallic nanoparticle vesicles for cancer
phototherapy. For collaboration
opportunities, please contact Cecilia
Pazman, Ph.D. at
pazmance@nhlbi.nih.gov.
Dated: December 15, 2015.
Michael Shmilovich,
Senior Licensing and Patenting Manager,
National Heart, Lung, and Blood Institute,
Office of Technology Transfer and
Development.
[FR Doc. 2015–32096 Filed 12–21–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive
Start-Up Option License: Potent and
Selective Analogues of Monamine
Transporters; Methods of Making; and
Uses Thereof
National Institutes of Health,
Public Health Service, HHS.
AGENCY:
E:\FR\FM\22DEN1.SGM
22DEN1
Federal Register / Vol. 80, No. 245 / Tuesday, December 22, 2015 / Notices
ACTION:
Notice.
This is a notice, in accordance
with 35 U.S.C. 209 and 37 CFR 404, that
the National Institute of Drug Abuse,
National Institutes of Health,
Department of Health and Human
Services is contemplating the grant of an
exclusive start-up option license to
practice the inventions embodied in the
following Patent Applications and all
related continuing and foreign patents/
patent applications for the technology
family to EncepHeal Therapeutics, Inc.,
located in Winston-Salem, North
Carolina.
DATES: Only written comments and/or
applications for a license which are
received by the NCI Technology
Transfer Center on or before January 6,
2016 will be considered.
ADDRESSES: Requests for copies of the
patent application, inquiries, comments,
and other materials relating to the
contemplated exclusive license should
be directed to Martha Lubet, Ph.D.,
Technology Transfer Specialist, NCI
TTC, 9609 Medical Center Drive, Room
IE350, and Rockville, MD 20850.
Telephone: (240) 276–5508. Facsimile:
(240) 276–5505. Email: lubetm@
mail.nih.gov.
SUPPLEMENTARY INFORMATION: This
invention concerns analogues of
modafinil and methods of using the
analogues for the treatment of substance
use disorders and sleep disorders.
The prospective exclusive start-up
option license will be royalty bearing
and will comply with the terms and
conditions of 35 U.S.C. 209 and 37 CFR
part 404. The prospective exclusive
start-up option may be granted unless
within fifteen (15) days from the date of
this published notice, the NCI receives
written evidence and argument that
establishes that the grant of the license
would not be consistent with the
requirements of 35 U.S.C. 209 and 37
CFR part 404.
Complete applications for a license in
the field of use filed in response to this
notice will be treated as objections to
the grant of the contemplated exclusive
start-up option license. Comments and
objections submitted to this notice will
not be made available for public
inspection and, to the extent permitted
by law, will not be released under the
Freedom of Information Act, 5 U.S.C.
552.
Intellectual Property:
U.S. provisional application 61/
774,878, filed March 8, 2013 entitled
‘‘Potent and Selective Inhibitors of
Monamine Transporters; Methods of
Making; and Uses Thereof’’ [HHS Ref.
No. E–073–2013/0–US–01];
mstockstill on DSK4VPTVN1PROD with NOTICES
SUMMARY:
VerDate Sep<11>2014
17:21 Dec 21, 2015
Jkt 238001
PCT application PCT/US2014/021514,
filed March 7, 2014 entitled ‘‘Potent and
Selective Analogues of: Monamine
Transporters; Methods of Making; and
Uses Thereof’’ [HHS Ref. No. E–073–
2013/0–PCT–02];
U.S. application 14/772,486, filed
September 3, 2015 entitled ‘‘Potent and
Selective Analogues of Monamine
Transporters; Methods of Making; and
Uses Thereof’’ [HHS Ref. No. E–073–
2013/0–US–06];
EPO application 14714043.8, filed
September 1, 2015 entitled ‘‘Potent and
Selective Analogues of Monamine
Transporters; Methods of Making; and
Uses Thereof’’ [HHS Ref. No. E–073–
2013/0–EP–05];
Australian application 2014225550,
filed September 8, 2015 entitled ‘‘Potent
and Selective Analogues of Monamine
Transporters; Methods of Making; and
Uses Thereof’’ [HHS Ref. No. E–073–
2013/0–AU–03];
Canadian application 2903746, filed
September 2, 2015 entitled ‘‘Potent and
Selective Analogues of Monamine
Transporters; Methods of Making; and
Uses Thereof’’ [HHS Ref. No. E–073–
2013/0–CA–04];
The patent rights to these inventions
have been assigned to and/or
exclusively licensed to the Government
of the United States of America.
The prospective exclusive start-up
option licensed territory may be
worldwide and the field of use may be
limited to: (a) Treatment of substance
use disorders and/or (b) treatment of
sleep disorders.
Upon the expiration or termination of
the exclusive start-up option license,
EncepHeal Therapeutics, Inc. will have
the exclusive right to execute a start-up
exclusive commercialization license
which will supersede and replace the
exclusive start-up option license with
no greater field of use and territory than
granted in the exclusive start-up option
license.
Dated: December 17, 2015.
Richard U. Rodriguez,
Associate Director, Technology Transfer
Center, National Cancer Institute.
[FR Doc. 2015–32141 Filed 12–21–15; 8:45 am]
79595
amended (5 U.S.C. App.), notice is
hereby given of the following meetings.
The meetings will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute on
Aging Initial Review Group; Clinical Aging
Review Committee.
Date: February 4–5, 2016.
Time: 2:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott and
Conference Center, 5701 Marinelli Road,
Bethesda, MD 20852.
Contact Person: Alicja L. Markowska,
Ph.D., DSC, National Institute on Aging,
National Institutes of Health, Gateway
Building 2C212, 7201 Wisconsin Avenue,
Bethesda, MD 20892, 301–496–9666
markowsa@nia.nih.gov.
Name of Committee: National Institute on
Aging Initial Review Group; Biological Aging
Review Committee.
Date: February 4–5, 2016.
Time: 2:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: Bethesda North Marriott and
Conference Center, 5701 Marinelli Road,
Bethesda, MD 20852.
Contact Person: Bita Nakhai, Ph.D.,
Scientific Review Branch, National Institute
on Aging, Gateway Bldg., 2C212, 7201
Wisconsin Avenue, Bethesda, MD 20814,
301–402–7701, nakhaib@nia.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.866, Aging Research,
National Institutes of Health, HHS)
Dated: December 16, 2015.
Melanie J. Gray,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2015–32036 Filed 12–21–15; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
BILLING CODE 4140–01–P
National Institutes of Health
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Eunice Kennedy Shriver National
Institute of Child Health & Human
Development; Notice of Meeting
National Institutes of Health
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
amended (5 U.S.C. App.), notice is
hereby given of a meeting of the
National Advisory Child Health and
Human Development Council.
National Institute on Aging; Notice of
Closed Meetings
Pursuant to section 10(d) of the
Federal Advisory Committee Act, as
PO 00000
Frm 00041
Fmt 4703
Sfmt 4703
E:\FR\FM\22DEN1.SGM
22DEN1
]]>Agencies
[Federal Register Volume 80, Number 245 (Tuesday, December 22, 2015)]
[Notices]
[Pages 79594-79595]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2015-32141]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Prospective Grant of an Exclusive Start-Up Option License: Potent
and Selective Analogues of Monamine Transporters; Methods of Making;
and Uses Thereof
AGENCY: National Institutes of Health, Public Health Service, HHS.
[[Page 79595]]
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: This is a notice, in accordance with 35 U.S.C. 209 and 37 CFR
404, that the National Institute of Drug Abuse, National Institutes of
Health, Department of Health and Human Services is contemplating the
grant of an exclusive start-up option license to practice the
inventions embodied in the following Patent Applications and all
related continuing and foreign patents/patent applications for the
technology family to EncepHeal Therapeutics, Inc., located in Winston-
Salem, North Carolina.
DATES: Only written comments and/or applications for a license which
are received by the NCI Technology Transfer Center on or before January
6, 2016 will be considered.
ADDRESSES: Requests for copies of the patent application, inquiries,
comments, and other materials relating to the contemplated exclusive
license should be directed to Martha Lubet, Ph.D., Technology Transfer
Specialist, NCI TTC, 9609 Medical Center Drive, Room IE350, and
Rockville, MD 20850. Telephone: (240) 276-5508. Facsimile: (240) 276-
5505. Email: lubetm@mail.nih.gov.
SUPPLEMENTARY INFORMATION: This invention concerns analogues of
modafinil and methods of using the analogues for the treatment of
substance use disorders and sleep disorders.
The prospective exclusive start-up option license will be royalty
bearing and will comply with the terms and conditions of 35 U.S.C. 209
and 37 CFR part 404. The prospective exclusive start-up option may be
granted unless within fifteen (15) days from the date of this published
notice, the NCI receives written evidence and argument that establishes
that the grant of the license would not be consistent with the
requirements of 35 U.S.C. 209 and 37 CFR part 404.
Complete applications for a license in the field of use filed in
response to this notice will be treated as objections to the grant of
the contemplated exclusive start-up option license. Comments and
objections submitted to this notice will not be made available for
public inspection and, to the extent permitted by law, will not be
released under the Freedom of Information Act, 5 U.S.C. 552.
Intellectual Property:
U.S. provisional application 61/774,878, filed March 8, 2013
entitled ``Potent and Selective Inhibitors of Monamine Transporters;
Methods of Making; and Uses Thereof'' [HHS Ref. No. E-073-2013/0-US-
01];
PCT application PCT/US2014/021514, filed March 7, 2014 entitled
``Potent and Selective Analogues of: Monamine Transporters; Methods of
Making; and Uses Thereof'' [HHS Ref. No. E-073-2013/0-PCT-02];
U.S. application 14/772,486, filed September 3, 2015 entitled
``Potent and Selective Analogues of Monamine Transporters; Methods of
Making; and Uses Thereof'' [HHS Ref. No. E-073-2013/0-US-06];
EPO application 14714043.8, filed September 1, 2015 entitled
``Potent and Selective Analogues of Monamine Transporters; Methods of
Making; and Uses Thereof'' [HHS Ref. No. E-073-2013/0-EP-05];
Australian application 2014225550, filed September 8, 2015 entitled
``Potent and Selective Analogues of Monamine Transporters; Methods of
Making; and Uses Thereof'' [HHS Ref. No. E-073-2013/0-AU-03];
Canadian application 2903746, filed September 2, 2015 entitled
``Potent and Selective Analogues of Monamine Transporters; Methods of
Making; and Uses Thereof'' [HHS Ref. No. E-073-2013/0-CA-04];
The patent rights to these inventions have been assigned to and/or
exclusively licensed to the Government of the United States of America.
The prospective exclusive start-up option licensed territory may be
worldwide and the field of use may be limited to: (a) Treatment of
substance use disorders and/or (b) treatment of sleep disorders.
Upon the expiration or termination of the exclusive start-up option
license, EncepHeal Therapeutics, Inc. will have the exclusive right to
execute a start-up exclusive commercialization license which will
supersede and replace the exclusive start-up option license with no
greater field of use and territory than granted in the exclusive start-
up option license.
Dated: December 17, 2015.
Richard U. Rodriguez,
Associate Director, Technology Transfer Center, National Cancer
Institute.
[FR Doc. 2015-32141 Filed 12-21-15; 8:45 am]
BILLING CODE 4140-01-P
